National clinical expert consensus statement: Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups
File(s)Expertpositionstatement2.pdf (290.75 KB)
Accepted version
Author(s)
Mullish, Benjamin H
Type
Report
Abstract
- Novel long-acting coronavirus prophylactic monoclonal antibody
therapies have been shown to be effective in preventing COVID19 in immunocompromised individuals who are at increased risk
from SARS-CoV-2.
- Prophylactic antibody therapies should be made available in a
timely manner to give an antibody immunity boost to vulnerable
patients.
- Real world evaluations should be co-implemented to provide
confidence of ongoing effectiveness.
- Successful delivery of a coronavirus prophylactic antibody
therapy programme would deliver significant benefits to
healthcare systems, communities and immunocompromised
individuals.
therapies have been shown to be effective in preventing COVID19 in immunocompromised individuals who are at increased risk
from SARS-CoV-2.
- Prophylactic antibody therapies should be made available in a
timely manner to give an antibody immunity boost to vulnerable
patients.
- Real world evaluations should be co-implemented to provide
confidence of ongoing effectiveness.
- Successful delivery of a coronavirus prophylactic antibody
therapy programme would deliver significant benefits to
healthcare systems, communities and immunocompromised
individuals.
Date Issued
2022-07-30
Citation
2022, pp.1-5
Start Page
1
End Page
5
Copyright Statement
© 2022 The Author(s).
Identifier
https://appg-vulnerablegroups.org/fileadmin/user_upload/Prophylactic_clinical_consensus_statement.pdf
Publication Status
Published